The Effects of Ursodeoxycholic Acid Pretreatment in an Experimental Setting of Extended Hepatectomy: A Feasibility Study.
extended hepatectomy
liver regeneration
liver resection
ursodeoxycholic acid
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Introduction Liver regeneration is an exceptionally complex process, orchestrated by a multitude of growth factors and cytokines. Tumor necrosis factor-alpha (TNF-a) and interleukin-6 (Il-6) have a pivotal role in the initiation of the regenerative response. Ursodeoxycholic acid (UDCA) exhibits a liver protective effect that enhances liver growth after injury. The aim of the present study is to evaluate the effect of UDCA in the circulating levels of TNF-a and Il-6 in rats undergoing extended 80% hepatectomy. Materials and methods Twenty-two male Sprague Dawley rats were randomly assigned in an experimental (UDCA group) and a control group. Mice in the UDCA-group received oral pretreatment of UDCA for two weeks preoperatively at a dosage of 25 mg/kg/day. An 80% hepatic resection was performed in both groups by resecting the middle, inferior right, and left lateral liver lobes. The experiment ended 48 hours postoperatively. Results UDCA pretreatment significantly depressed circulating levels of both TNF-a and Il-6 after the conclusion of the experiment as compared to the control group (p=0.001 and p=0.01, respectively). Furthermore, TNF-a levels were significantly reduced before the institution of liver injury (p=0.02). Mice in the UDCA-group exhibited better liver growth as demonstrated by significantly increased Ki-67 and mitotic rate (p=0.04 and p=0.02, respectively). Finally, the liver regeneration rate (LRR) was significantly elevated in the experimental group (UDCA group, 54.5% vs control group, 35.8%; p=0.002) signifying enhanced liver growth kinetics. Conclusion UDCA reduces the expression of TNF-a and Il-6 during the priming phase of liver regeneration. An 80% hepatectomy model of acute liver failure exhibited enhanced liver regeneration in the experimental group, plausibly due to the immunomodulatory effects of UDCA.
Identifiants
pubmed: 33489534
doi: 10.7759/cureus.12120
pmc: PMC7810173
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12120Informations de copyright
Copyright © 2020, Paspala et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G887-97
pubmed: 20689055
Hepatology. 1996 May;23(5):1159-66
pubmed: 8621149
Nat Protoc. 2008;3(7):1167-70
pubmed: 18600221
J Surg Res. 2001 Dec;101(2):157-65
pubmed: 11735271
Gastroenterology. 1996 Jun;110(6):1854-62
pubmed: 8964411
Gut. 2000 Aug;47(2):309-12
pubmed: 10896929
PLoS One. 2014 Apr 24;9(4):e96053
pubmed: 24763697
BMC Gastroenterol. 2013 Oct 30;13:155
pubmed: 24172289
Acta Pharmacol Sin. 2018 Sep;39(9):1493-1500
pubmed: 29770794
Liver Int. 2008 Jan;28(1):3-11
pubmed: 18028319
J Hepatol. 2002 Apr;36(4):534-42
pubmed: 11943426
Eur J Pharmacol. 2008 Jan 6;578(1):57-64
pubmed: 17888421
J Cell Physiol. 2007 Nov;213(2):286-300
pubmed: 17559071
Science. 1996 Nov 22;274(5291):1379-83
pubmed: 8910279
Cell Death Dis. 2020 Jan 27;11(1):70
pubmed: 31988281
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1441-6
pubmed: 9037072
PLoS One. 2017 Jun 30;12(6):e0180673
pubmed: 28665991
Hepatology. 2003 Sep;38(3):674-82
pubmed: 12939594
Hepatol Res. 2009 Aug;39(8):814-21
pubmed: 19473430
Liver Transpl. 2015 Jun;21(6):792-800
pubmed: 25772848
Science. 2006 Apr 14;312(5771):233-6
pubmed: 16614213
Mol Cell Biol. 1997 Jul;17(7):3600-13
pubmed: 9199295
Cancer Res. 1999 Aug 15;59(16):3954-60
pubmed: 10463591